Fate Therapeutics Q3 2023 Gaap EPS $(0.46) Beats $(0.57) Estimate, Sales $1.94M Beat $890.00K Estimate
Portfolio Pulse from saritha@benzinga.com
Fate Therapeutics (NASDAQ:FATE) reported Q3 2023 GAAP EPS of $(0.46), beating the estimate of $(0.57) by 19.3%. This is a 46.51% increase over losses from the same period last year. The company also reported quarterly sales of $1.94M, beating the estimate of $890.00K by 118.43%, but this is a 87.02% decrease over sales from the same period last year.
November 08, 2023 | 9:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Fate Therapeutics reported better than expected Q3 2023 earnings but a significant decrease in sales YoY.
While Fate Therapeutics beat earnings estimates, which is generally positive for the stock, the significant decrease in sales compared to the same period last year could be a concern for investors, potentially offsetting the positive earnings news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100